2023 World Conference on Lung Cancer (Posters)-EP10.01. Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis

EP10.01. Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy and safety of nintedanib and docetaxel in patients with advanced/metastatic lung adenocarcinoma in different lines of treatment. The primary endpoints were progression-free survival (PFS) and best objective response, and the secondary endpoint was overall survival. The data were sourced from two centers in Slovenia and one in Croatia, and 96 patients were retrospectively analyzed after treatment with chemotherapy and immune checkpoint inhibitor failure. <br /><br />The results showed that across all lines, the median PFS was 3.0 months, and the median overall survival was 8.0 months. The objective response rate was 18.8%, and the disease control rate was 57.3%. The majority of patients received docetaxel plus nintedanib as third-line therapy, following first-line platinum-based chemotherapy and second-line immune checkpoint inhibitor monotherapy. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after a first-line combination chemotherapy-immune checkpoint inhibitor therapy. <br /><br />Fifty-three patients (55.2%) experienced adverse events, with gastrointestinal issues like diarrhea and increased liver enzyme levels being the most frequent. <br /><br />In conclusion, this treatment modality combining nintedanib and docetaxel could be considered effective with an acceptable toxicity profile in patients with advanced lung adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

efficacy

safety

nintedanib

docetaxel

lung adenocarcinoma

progression-free survival

overall survival

chemotherapy

immune checkpoint inhibitor

adverse events